Australian Life Sciences Stock News

Santos (ASX:STO) has reported higher proved plus probable reserves and larger carbon capture and storage resources, placing its emissions management plans alongside core production firmly in focus for investors tracking sustainability themes. See our latest analysis for Santos. At a share price of A$6.70, Santos has had a 6.18% 1 month share price return and an 8.94% year to date share price return. Meanwhile, the 1 year total shareholder return of 1.26% and 5 year total shareholder return of...

In the past quarter, James Hardie Industries plc reported third-quarter 2025 sales of US$1,239.8 million, up from US$953.3 million a year earlier, while net income fell to US$68.7 million from US$141.7 million and basic earnings per share from continuing operations declined to US$0.12 from US$0.33. Despite the weaker headline profit, the company exceeded analyst expectations for adjusted earnings and revenue, highlighting strong sales growth supported by the early benefits of its AZEK...

ANZ Group Holdings (ASX:ANZ) is back in focus after revealing first quarter costs came in lower than analysts had expected, a surprise that has sharpened attention on the bank’s efficiency and profit potential. See our latest analysis for ANZ Group Holdings. The cost surprise has arrived on top of strong recent momentum, with ANZ’s 7 day share price return of 10.48% and 30 day share price return of 12.40% adding to a 1 year total shareholder return of 37.44%. This suggests sentiment has been...

G8 Education recently announced a large A$350,000,000 non-cash goodwill impairment for FY25, alongside suspending its final dividend and pausing its on-market share buyback in response to weaker sector conditions and softer earnings expectations. Despite these conservative capital measures, the company has reaffirmed its FY25 EBIT guidance, underscoring management’s view that underlying operations remain broadly stable even as accounting values are reset. We’ll now examine how this sizeable...

Why Michael Powell’s appointment matters for DroneShield DroneShield (ASX:DRO) has appointed Michael Powell as Chief Operating Officer, following a period of accelerated expansion, rising demand from defence, government and critical infrastructure customers, and a major manufacturing build out in Alexandria, New South Wales. See our latest analysis for DroneShield. The appointment comes as the A$3.03 share price sits below recent highs, with a 30 day share price return of a 24% decline...

Westpac Banking Corporation has reported first-quarter FY26 unaudited statutory net profit of A$1.90 billion, with revenue rising as higher net interest income offset softer non-interest income, alongside growth in lending and deposits. The bank also highlighted progress in its technology agenda, including company-wide AI training and new digital platforms, which management links to better customer service, productivity and operational resilience. We’ll now examine how Westpac’s profit...

Viva Leisure (ASX:VVA) has set out its H1 2026 picture with investors looking closely at how its recent run of numbers stacks up, after the company booked H2 2025 revenue of A$112.3 million with basic EPS of A$0.0329 and net income of A$3.3 million, on top of H1 2025 revenue of A$99.0 million and EPS of A$0.0195. Over recent halves the company has seen revenue move from A$83.5 million and EPS of A$0.0187 in H2 2024 to A$99.0 million and A$0.0195 in H1 2025, before reaching A$112.3 million and...

MFF Capital Investments (ASX:MFF) has released its H1 2026 scorecard, with recent half-year figures showing H2 2025 revenue of A$68.5 million and basic EPS of A$0.09, alongside H1 2025 revenue of A$562.9 million and basic EPS of A$0.66. These are set against H2 2024 revenue of A$449.6 million and basic EPS of A$0.52. The company has also reported trailing 12‑month revenue of A$631.4 million with basic EPS of A$0.74 in H2 2025 and A$1.18 on A$1.0 billion of revenue in H1 2025, giving investors...

In February 2026, Mesoblast reported data from patients treated under the U.S. Emergency Investigational New Drug program showing that its FDA-approved cell therapy Ryoncil® (remestemcel-L-rknd) achieved similarly high survival outcomes in steroid-refractory acute graft-versus-host disease across children and adults, at different treatment lines and regardless of ruxolitinib use or resistance. The findings, which highlighted better completion of treatment and survival when Ryoncil was used...

Insurance Australia Group (ASX:IAG) has put up another set of solid headline numbers for H1 2026, with trailing twelve month revenue of about A$17.4b and basic EPS of A$0.57 coming off net income of A$1,359m, while the latest reported half in 2025 delivered revenue of A$8.7b and EPS of A$0.25 on net income of A$581m. Over the past few reported halves the company has seen revenue move from A$8.1b in H2 2024 to A$8.7b in H1 2025 and A$8.7b in H2 2025, alongside EPS shifting from A$0.21 to...

Oneview Healthcare (ASX:ONE) has put fresh numbers on the table for FY 2025, reporting first half revenue of €6.3 million and a basic EPS loss of €0.01. Trailing twelve month revenue stands at €11.6 million with a basic EPS loss of €0.016452. Over recent periods the company’s revenue has moved from €4.7 million in the first half of 2024 to €5.2 million in the second half of 2024 and then to €6.3 million in the first half of 2025. Across the same periods, half year basic EPS figures have...

CAR Group (ASX:CAR) is back in focus after its latest half year earnings, where revenue reached A$625.79 million and net profit came in at A$143.34 million, alongside a higher interim dividend. See our latest analysis for CAR Group. Despite the solid half year update and higher dividend, the share price has had a tougher run, with a 30 day share price return of a 17.67% decline and a year to date share price return of an 18.79% decline. The 1 year total shareholder return of a 32.67% decline...

Northern Star Resources (ASX:NST) has reported another solid set of numbers for H1 2026, with the latest reported half year in H2 2025 showing revenue of A$3.5b and basic EPS of A$0.68, underpinned by net income of A$833.3m. The company has seen revenue move from A$2.7b and EPS of A$0.38 in H2 2024 to A$2.9b and EPS of A$0.44 in H1 2025, then to A$3.5b and EPS of A$0.68 in H2 2025. This sets up a trailing twelve month net income of A$1.5b and EPS of A$1.16. With net profit margins running at...

In early 2026, Electro Optic Systems (EOS) issued a detailed rebuttal to US short seller Grizzly Research’s report, clarifying its cash position, explaining that a disputed US$80 million South Korean high‑energy laser contract is conditional and excluded from its confirmed A$459 million order backlog, and defending the MARSS Group acquisition. At the same time, EOS signed a collaboration agreement with Turkish defence company ROKETSAN and disclosed a conditional high‑energy laser contract in...

Pro Medicus (ASX:PME) has just posted its H1 2026 scorecard, headlined by trailing 12 month revenue of A$241.1 million alongside basic EPS of A$2.25, as the company continues to convert its imaging software footprint into solid top and bottom line figures. The company has seen revenue move from A$184.6 million to A$241.1 million across recent trailing 12 month periods, with basic EPS stepping up from A$0.94 to A$2.25 over the same horizon. Reported net profit margin has shifted sharply higher...

AMP (ASX:AMP) has put fresh numbers on the table for FY 2025, reporting first half revenue of A$1.4 billion and basic EPS of A$0.039. This helps set the tone for how the year is shaping up after a mixed FY 2024. The company reported revenue of A$1.4 billion in the first half of 2024 and a loss of A$392 million in the second half. Over the same period, basic EPS moved from A$0.0387 to A$0.0185, before reaching A$0.039 in the latest half. For investors, a key focus now is how these results...

In February 2026, Expensify, Inc. announced an expanded partnership with Xero, offering new small-business customers six months free on Xero’s Business Edition and 50% off Expensify’s annual plan for six months when signing up through each other’s platforms. By pairing cross-platform discounts with coordinated onboarding and in-app promotion, the collaboration could deepen usage across both ecosystems and tighten the link between expense management and accounting workflows. Next, we’ll...

BHP Group (ASX:BHP) is back shipping iron ore from Port Hedland after Tropical Cyclone Mitchell temporarily halted exports, while also committing more capital to large copper, gold, and silver projects in Argentina's Vicuña District. See our latest analysis for BHP Group. Those developments come as BHP’s share price, now at A$52.09, has shown firm positive momentum, with a 9.48% 1 month share price return and a 21.85% 3 month share price return, while the 1 year total shareholder return is...

Paladin Energy reported its December 2025 half-year results, with quarterly sales rising to US$102.38 million and net income to US$6.27 million, while recent equity raisings of A$300 million plus a A$100 million share purchase plan and a syndicated debt restructure bolstered its liquidity to fund Langer Heinrich and Patterson Lake South. An interesting takeaway is that despite six‑month net income of just US$0.872 million, Paladin has materially strengthened its balance sheet to support...

Commonwealth Bank of Australia has reported higher half‑year earnings to 31 December 2025, with net income rising to A$5,367 million and basic earnings per share from continuing operations lifting to A$3.237, and it has declared a fully franked interim dividend of A$2.35 per share payable on 30 March 2026. By combining record cash earnings with an increased fully franked dividend and continued investment in technology and AI, the bank is signalling confidence in its core franchise strength...

What triggered the latest move in Deep Yellow shares? Deep Yellow (ASX:DYL) has been in focus after confirming uranium mineralisation at the S Bend prospect near its Tumas Project, as well as announcing that Managing Director and CEO John Borshoff will step down immediately. See our latest analysis for Deep Yellow. At the current share price of A$2.47, Deep Yellow has seen a 22.89% 1 month share price return and a 54.86% 3 month share price return. Its 1 year total shareholder return of...

Insiders who purchased Canadian Phosphate Limited ( ASX:CP8 ) shares in the past 12 months are unlikely to be deeply...

What Evolution’s record half year means for shareholders Evolution Mining (ASX:EVN) has reported record half year numbers, with revenue of A$2,794.35 million and net profit of A$766.57 million, alongside a fully franked interim dividend of A$0.20 per share. For you as an investor, the combination of higher earnings per share, lower net debt over the past two years and a materially larger dividend sits at the centre of the current investment story. See our latest analysis for Evolution...

Neuren Pharmaceuticals (ASX:NEU) has announced a new share buy-back program, authorising repurchases of up to 6,350,631 shares, or 5% of its issued capital, through to March 2027. See our latest analysis for Neuren Pharmaceuticals. The buy-back comes after a sharp 30 day share price return of around a 30% decline and a 90 day share price return of about a 29% decline, even though the 1 year and multi year total shareholder returns remain positive and very strong. This suggests recent selling...